A Role for Virally Induced Reactive Oxygen Species in Kaposi's Sarcoma Herpesvirus Tumorigenesis

Overview

Journal Antioxid Redox Signal

Specialty Endocrinology

Date 2012 Jul 4

PMID 22746102

Citations 37

Authors

Qi Ma

Lucas E Cavallin

Howard J Leung

Chiara Chiozzini

Pascal J Goldschmidt-Clermont

Enrique A Mesri

Affiliations

Soon will be listed here.

Abstract

Aims: Kaposi's sarcoma (KS), caused by the Kaposi's sarcoma herpesvirus (KSHV), is an AIDS-associated cancer characterized by angiogenesis and proliferation of spindle cells. Rac1-activated reactive oxygen species (ROS) production has been implicated in KS tumorigenesis. We used an animal model of KSHV-induced Kaposi's sarcomagenesis (mECK36) to study the role of ROS in KS and the efficacy of N-acetyl l-cysteine (NAC) in inhibiting or preventing KS.

Results: Signaling by the KSHV early lytic gene viral G protein-coupled receptor (vGPCR) activated ROS production in mECK36 cells via a Rac1-NADPH oxidase pathway. Induction of the lytic cycle in KSHV-infected KS spindle cells upregulated ROS along with upregulation of vGPCR expression. We also found that expression of the major latent transcript in 293 cells increased ROS levels. ROS scavenging with NAC halted mECK36 tumor growth in a KSHV-specific manner. NAC inhibited KSHV latent gene expression as well as tumor angiogenesis and lymphangiogenesis. These effects correlated with the reduction of vascular endothelial growth factor (VEGF), c-myc, and cyclin D1, and could be explained on the basis of inhibition of STAT3 tyrosine phosphorylation. NAC prevented mECK36 de novo tumor formation. Molecular analysis of NAC-resistant tumors revealed a strong upregulation of Rac1 and p40(PHOX).

Innovation And Conclusion: Our results demonstrate that ROS-induction by KSHV plays a causal role in KS oncogenesis by promoting proliferation and angiogenesis. Our results show that both ROS and their molecular sources can be targeted therapeutically using NAC or other Food and Drug Administration (FDA)-approved inhibitors for prevention and treatment of AIDS-KS.

Citing Articles

In Vitro Studies of Pegylated Magnetite Nanoparticles in a Cellular Model of Viral Oncogenesis: Initial Studies to Evaluate Their Potential as a Future Theranostic Tool.

Principe G, Lezcano V, Tiburzi S, Miravalles A, Rivero P, Montiel Schneider M Pharmaceutics. 2023; 15(2).

PMID: 36839809 PMC: 9967771. DOI: 10.3390/pharmaceutics15020488.

A major role for Nrf2 transcription factors in cell transformation by KSHV encoded oncogenes.

Sapochnik D, Raimondi A, Medina V, Naipauer J, Mesri E, Coso O Front Oncol. 2022; 12:890825.

PMID: 36212441 PMC: 9534600. DOI: 10.3389/fonc.2022.890825.

Metabolic landscapes in sarcomas.

Miallot R, Galland F, Millet V, Blay J, Naquet P J Hematol Oncol. 2021; 14(1):114.

PMID: 34294128 PMC: 8296645. DOI: 10.1186/s13045-021-01125-y.

A Non-Coding RNA Network Involved in KSHV Tumorigenesis.

Naipauer J, Sola M, Salyakina D, Rosario S, Williams S, Coso O Front Oncol. 2021; 11:687629.

PMID: 34222014 PMC: 8242244. DOI: 10.3389/fonc.2021.687629.

Targeting the signaling in Epstein-Barr virus-associated diseases: mechanism, regulation, and clinical study.

Cao Y, Xie L, Shi F, Tang M, Li Y, Hu J Signal Transduct Target Ther. 2021; 6(1):15.

PMID: 33436584 PMC: 7801793. DOI: 10.1038/s41392-020-00376-4.

References

Kirshner J, Staskus K, Haase A, Lagunoff M, Ganem D . Expression of the open reading frame 74 (G-protein-coupled receptor) gene of Kaposi's sarcoma (KS)-associated herpesvirus: implications for KS pathogenesis. J Virol. 1999; 73(7):6006-14. PMC: 112661. DOI: 10.1128/JVI.73.7.6006-6014.1999. View

Irani K, Xia Y, Zweier J, Sollott S, Der C, Fearon E . Mitogenic signaling mediated by oxidants in Ras-transformed fibroblasts. Science. 1997; 275(5306):1649-52. DOI: 10.1126/science.275.5306.1649. View

Yoon S, Woo S, Kang J, Kim K, Kwon M, Park S . STAT3 transcriptional factor activated by reactive oxygen species induces IL6 in starvation-induced autophagy of cancer cells. Autophagy. 2010; 6(8):1125-38. DOI: 10.4161/auto.6.8.13547. View

Safai B, Johnson K, Myskowski P, Koziner B, Yang S, Cunningham-Rundles S . The natural history of Kaposi's sarcoma in the acquired immunodeficiency syndrome. Ann Intern Med. 1985; 103(5):744-50. DOI: 10.7326/0003-4819-103-5-744. View

Nguyen H, Magaret A, Kitahata M, Van Rompaey S, Wald A, Casper C . Persistent Kaposi sarcoma in the era of highly active antiretroviral therapy: characterizing the predictors of clinical response. AIDS. 2008; 22(8):937-45. PMC: 2730951. DOI: 10.1097/QAD.0b013e3282ff6275. View

Gao P, Zhang H, Dinavahi R, Li F, Xiang Y, Raman V . HIF-dependent antitumorigenic effect of antioxidants in vivo. Cancer Cell. 2007; 12(3):230-8. PMC: 2084208. DOI: 10.1016/j.ccr.2007.08.004. View

De Rosa S, Zaretsky M, Dubs J, Roederer M, Anderson M, Green A . N-acetylcysteine replenishes glutathione in HIV infection. Eur J Clin Invest. 2000; 30(10):915-29. DOI: 10.1046/j.1365-2362.2000.00736.x. View

Yang T, Chen S, Leach M, Manfra D, Homey B, Wiekowski M . Transgenic expression of the chemokine receptor encoded by human herpesvirus 8 induces an angioproliferative disease resembling Kaposi's sarcoma. J Exp Med. 2000; 191(3):445-54. PMC: 2195818. DOI: 10.1084/jem.191.3.445. View

Koon H, Bubley G, Pantanowitz L, Masiello D, Smith B, Crosby K . Imatinib-induced regression of AIDS-related Kaposi's sarcoma. J Clin Oncol. 2004; 23(5):982-9. DOI: 10.1200/JCO.2005.06.079. View

10.

Li X, Feng J, Sun R . Oxidative stress induces reactivation of Kaposi's sarcoma-associated herpesvirus and death of primary effusion lymphoma cells. J Virol. 2010; 85(2):715-24. PMC: 3020037. DOI: 10.1128/JVI.01742-10. View

11.

Krown S . Therapy of AIDS-associated Kaposi's sarcoma: targeting pathogenetic mechanisms. Hematol Oncol Clin North Am. 2003; 17(3):763-83. DOI: 10.1016/s0889-8588(03)00042-x. View

12.

De Rosa S, Dubs J, Roederer M, Anderson M, Ela S, Deresinski S . Glutathione deficiency is associated with impaired survival in HIV disease. Proc Natl Acad Sci U S A. 1997; 94(5):1967-72. PMC: 20026. DOI: 10.1073/pnas.94.5.1967. View

13.

Wade M, Wahl G . c-Myc, genome instability, and tumorigenesis: the devil is in the details. Curr Top Microbiol Immunol. 2006; 302:169-203. DOI: 10.1007/3-540-32952-8_7. View

14.

Owusu-Ansah E, Yavari A, Mandal S, Banerjee U . Distinct mitochondrial retrograde signals control the G1-S cell cycle checkpoint. Nat Genet. 2008; 40(3):356-61. DOI: 10.1038/ng.2007.50. View

15.

Albini A, Morini M, DAgostini F, Ferrari N, Campelli F, Arena G . Inhibition of angiogenesis-driven Kaposi's sarcoma tumor growth in nude mice by oral N-acetylcysteine. Cancer Res. 2001; 61(22):8171-8. View

16.

Cesarman E, Mesri E, Gershengorn M . Viral G protein-coupled receptor and Kaposi's sarcoma: a model of paracrine neoplasia?. J Exp Med. 2000; 191(3):417-22. PMC: 2195817. DOI: 10.1084/jem.191.3.417. View

17.

Atkuri K, Mantovani J, Herzenberg L, Herzenberg L . N-Acetylcysteine--a safe antidote for cysteine/glutathione deficiency. Curr Opin Pharmacol. 2007; 7(4):355-9. PMC: 4540061. DOI: 10.1016/j.coph.2007.04.005. View

18.

Shin J, Huggenberger R, Detmar M . Transcriptional profiling of VEGF-A and VEGF-C target genes in lymphatic endothelium reveals endothelial-specific molecule-1 as a novel mediator of lymphangiogenesis. Blood. 2008; 112(6):2318-26. PMC: 2532805. DOI: 10.1182/blood-2008-05-156331. View

19.

Menon S, Sarsour E, Kalen A, Venkataraman S, Hitchler M, Domann F . Superoxide signaling mediates N-acetyl-L-cysteine-induced G1 arrest: regulatory role of cyclin D1 and manganese superoxide dismutase. Cancer Res. 2007; 67(13):6392-9. DOI: 10.1158/0008-5472.CAN-07-0225. View

20.

Chung A, Ferrara N . Developmental and pathological angiogenesis. Annu Rev Cell Dev Biol. 2011; 27:563-84. DOI: 10.1146/annurev-cellbio-092910-154002. View